This study from Japan reported outcomes of 116 patients with pelvic bone sarcoma treated by surgery (n=57) and particle beam (n=59, 55 carbon ion, 4 proton). For all 116 patients, the 3-year OS, LC, and metastasis-free survival (MFS) rates in the surgery group were 81.8%, 74.2%, and 64.4%, and in the particle beam group 84.4%, 89.1% and 73.1%. For matched 24 patients in each group, 3-year OS, LC, and MFS rates in the surgery group were 82.9%, 66.0% and 78.45%, the rates in the particle beam group were 64.9%, 86.4% and 62.6%, respectively. No significant differences in OS (P = 0.13), LC (P = 0.283), or MFS (P = 0.553) rates were observed. In patients with chordomas, the LC in the particle beam group was significantly better than in the surgery group (P = 0.011). The authors concluded that particle beam therapy might be an alternative treatment option for patients with pelvic bone sarcomas.